DIVISION OF DISEASE CONTROL



20 20

INTRODUCTION

OVERVIEW

This annual report provides an epidemiologic summary of conditions reported to the Philadelphia Department of Public Health (PDPH) Division of Disease Control (DDC) in 2020. There are currently 76 medical conditions that health care providers or laboratories must report to the DDC (see page 61). The report highlights the most commonly reported conditions and those of public health importance. Data regarding cases of HIV/AIDS are reported separately by the Division of HIV Health (DHH).

For additional information, please visit: https://hip.phila.gov/

CASE DEFINITION

A standard reporting case definition has been set for most reportable conditions by the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE). These case definitions may differ from the criteria used to make a clinical diagnosis.

Case definitions can be found at : https://wwwn.cdc.gov/nndss/

HOW DDC CAN ASSIST HEALTH-CARE PROVIDERS

If you suspect a disease outbreak or that a patient is infected with a disease of urgent public health importance, DDC can facilitate diagnostic testing and assist with infection control and disease management. To speak with a medical specialist, please call 215-685-6748. For urgent after hours immediate reporting and consultation, please call 215-686-4514 and ask for the Division of Disease Control on-call staff.

LOCATION

STD testing and services at Health Center 1 and Directly Observed Therapy (DOT) services at the Lawrence F. Flick Memorial Center are now both located at:

> Constitution Health Plaza 1930 S Broad St Philadelphia, PA 19145

DISEASE SURVEILLANCE

In response to the emergence of the COVID-19 pandemic during 2020, the Philadelphia Department of Public Health enacted several citywide, non-pharmaceutical interventions to mitigate the spread of this novel pathogen, including restrictions on non-essential, in-person businesses and activities, indoor capacity limits, and masking mandates. Although these local mitigation strategies along with measures implemented at the state and federal level aimed to limit transmission of COVID-19, the strategies also likely decreased community transmission of other communicable diseases. In addition, the impact of the COVID-19 pandemic on healthcare access for other acute illnesses and preventative care may also have decreased the identification and diagnosis of communicable diseases among City residents during 2020.

TABLE OF CONTENTS

1	OVERVIEW	DISEASE REPORTING TRENDS REGIONAL OVERVIEW	6 8
2	CENTRAL NERVOUS SYSTEM INFECTIONS & SEPSIS	GROUP A STREPTOCOCCUS HAEMOPHILUS INFLUENZAE LISTERIOSIS MENINGITIS, ASEPTIC STREPTOCOCCUS PNEUMONIAE	11 12 13 14 15
3	GASTROINTESTINAL INFECTIONS	OVERVIEW CAMPYLOBACTERIOSIS CRYPTOSPORIDIOSIS GIARDIASIS SALMONELLOSIS SHIGELLOSIS	18 20 21 22 23 25
4	HEALTHCARE- ASSOCIATED INFECTIONS	OVERVIEW CARBAPENEM - RESISTANT ENTEROBACTERIACEAE	27 28
5	RESPIRATORY INFECTIONS	INFLUENZA LEGIONELLOSIS TUBERCULOSIS	30 31 32
6	SEXUALLY TRANSMITTED DISEASES	OVERVIEW CHLAMYDIA GONORRHEA SYPHILIS-PRIMARY & SECONDARY SYPHILIS-LATENT	34 36 38 40 42
7	VACCINE-PREVENTABLE DISEASES	CHICKEN POX MENINGOCOCCAL DISEASE MUMPS PERTUSSIS	45 47 49 50
8	VECTORBORNE DISEASES	TICKBORNE INFECTIONS ARBOVIRAL INFECTIONS LYME DISEASE MALARIA WEST NILE VIRUS	51 52 53 54 54
9	VIRAL HEPATITIS INFECTIONS	HEPATITIS A HEPATITIS B & C-ACUTE HEPATITIS B-CHRONIC HEPATITIS B & C-PERINATAL HEPATITIS C-CHRONIC	56 57 58 59 60
10	REPORTING DISEASES & CONDITIONS	NOTIFIABLE DISEASE LIST REPORT FORM	62 63

OVERVIEW

DISEASE REPORTING TRENDS REGIONAL OVERVIEW

DISEASE REPORTING TRENDS

Reports of Communicable Diseases Per Year: Philadelphia, 2011-2020


	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Amebiasis	9	11	13	15	8	2	13	14	18	3
Animal Bites/Exposures	1,513	1,598	1,586	1,644	1,718	1,722	1,574	1,486	1,547	1,103
Anthrax	0	0	0	0	0	0	0	0	0	0
Babesiosis	1	0	1	1	3	2	5	4	4	3
Botulism	2	2	2	1	о	3	3	1	0	0
Brucellosis	0	1	1	0	1	0	1	0	0	1
Campylobacteriosis	141	182	103	167	211	203	233	270	274	197
Carbapenem-resistant Enterobacteriaceae (CRE)		-	_	-	_		-	308	234	234
Chlamydia trachomatis	20,471	20,803	19,570	18,935	19,169	19,959	21,119	20,206	20,354	15,834
Cholera	0	1	0	0	0	0	0	0	0	0
Cryptosporidiosis	14	18	58	30	26	48	51	38	31	24
Cyclosporiasis	0	1	0	1	3	4	3	0	3	2
Dengue Fever	1	1	11	0	5	3	0	1	13	1
Diphtheria	0	0	0	0	0	0	0	0	0	0
Escherichia coli, Shiga Toxin-Producing (STEC)	9	12	6	10	11	25	19	28	41	27
Giardiasis	43	60	76	65	61	58	66	59	75	47
Gonorrhea	6,761	7,293	6,303	5,961	6,260	6,957	7,288	7,205	7,043	7,302
Guillian-Barre Syndrome	0	0	1	1	4	3	7	0	1	<u> </u>
Haemophilus influenzae [Type B]	22 [2]	39 [1]	26 [0]	23 [1]	24 [2]	36 [3]	49 [1]	27[0]	37 [1]	24[0]
Hansen's Disease (Leprosy)	0	1	0	0	1	0	1	1	0	0
Hepatitis A	8	2	6	6	6	9	19	21	454	25
Hepatitis B, Acute	7	4	5	7	8	5	10	13	44	18
Hepatitis C, Acute	0	20	42	67	79	130	155	183	147	121
Histoplasmosis	0	1	0	0	2	1	3	2	1	2
Legionellosis	64	29	61	42	53	34	66	91	56	39
Leptospirosis	0	1	0	0	0	0	0	1	1	3
Listeriosis	2	6	10	3	2	2	0	8	2	4
Lyme Disease	301	191	189	140	252	236	264	260	181	143
Malaria	19	13	21	30	18	22	30	40	45	7
Measles	0	2	0	0	0	0	0	1	0	0
Meningitis, Aseptic	104	92	124	60	55	48	55	41	36	15
Meningitis, Bacterial	12	5	3	0	2	3	6	7	7	3
Meningococcal Infections	4	6	3	2	0	2	0	1	6	14

DISEASE REPORTING TRENDS (Cont.)

Reports of Communicable Diseases Per Year: Philadelphia, 2011-2020 (Cont.)

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Mumps	21	4	3	0	1	5	8	24	259	5
Pertussis	49	268	86	127	111	101	107	72	93	32
Plague	0	0	0	0	0	0	0	0	0	0
Poliomyelitis	0	0	0	0	0	0	0	0	0	0
Rabies (Human)	0	0	0	0	0	0	0	0	0	0
Rickettsial Diseases, Including RMSF	4	12	8	10	8	5	7	3	8	1
Rubella, Including Congenital Rubella Syndrome	0	0	0	1	0	0	0	0	0	0
Salmonellosis, Excluding Typhoid	301	305	284	229	237	188	219	213	244	175
Shigellosis	41	48	66	66	90	311	91	92	86	78
Staphylococcus aureus, vancomycin insensitive	0	0	0	1	0	0	0	4	1	0
Streptococcus Pneumoniae, Invasive	158	103	149	101	119	136	161	157	197	123
Streptococcus, Invasive gp. A [TSS]	73 [0]	61 [0]	56 [0]	95 [0]	90 [0]	78 [1]	113 [0]	156[0]	181[0]	179[0]
Syphilis-Primary & Secondary	207	269	278	308	314	428	459	408	470	511
Syphilis-Congenital	4	5	1	4	4	5	6	3	6	6
Syphilis-Total	698	798	962	894	916	927	1,256	1,214	1,262	1,374
Tetanus	0	0	0	0	0	0	0	0	0	0
Toxic Shock Syndrome, Staphylococcal	0	1	0	1	0	0	0	0	0	0
Tuberculosis	101	86	89	78	72	74	75	78	74	61
Tularemia	0	0	0	0	0	0	0	0	0	0
Typhoid Fever	3	2	1	5	3	1	3	1	1	4
Varicella (Chicken Pox only)	262	118	167	118	123	111	104	113	77	20
Vibrio SPP. Other	1	0	0	4	6	7	11	13	11	6
West Nile Virus	1	9	3	5	0	4	3	17	3	4
Yellow Fever	0	0	0	0	5	0	0	0	0	0

REGIONAL OVERVIEW



Total Population Count by Age and Region: Philadelphia, 2010

	NE	NW	N	cc/s	W/SW	Total
Age						
0-4 Yrs	23,127	5,055	41,227	13,888	17,760	101,057
5-17 Yrs	56,820	12,189	103,578	26,046	44,165	242,798
18-34 Yrs	86,479	29,154	149,432	95,613	89,090	449,768
35-60 Yrs	122,363	34,069	171,370	81,045	81,124	489,971
>60 Yrs	67,760	20,906	69,859	43,269	40,698	242,492
Total	356,549	101,373	535,466	259,861	272,837	1,526,086

*Data according to the U.S. Census Bureau

REGIONAL OVERVIEW (Cont.)

	NE	NW	Ν	cc/s	w/sw	Missing	Total
	n	n	n	n	n	n	n
Campylobacteriosis	66	8	50	28	37	8	197
Carbapenem-resistant Enterobacteriaceae	33	14	59	24	35	69	234
Chlamydia	2,299	538	7,519	1,522	3,385	571	15,834
Giardiasis	7	0	13	17	9	1	47
Gonorrhea	767	219	3,378	896	1,726	316	7,302
Hepatitis C, Chronic (RNA +)	310	31	367	96	110	109	1023
Influenza (Hospitalized)	171	42	336	147	192	34	922
Lyme Disease	45	28	30	28	12	о	143
Meningitis, Aseptic	4	0	3	1	4	3	15
Pertussis	5	1	11	10	4	1	32
Salmonellosis	31	6	53	25	51	9	175
Shigellosis	10	1	14	18	29	6	78
Streptococcus Pneumoniae, Invasive	16	6	52	18	15	16	123
Streptococcus, Invasive gp A	39	6	68	31	23	12	179
Syphilis-Early Latent	54	27	251	126	129	5	592
Syphilis-Primary & Secondary	48	20	198	109	116	20	511
Tuberculosis	17	<6	18	13	12	0	61
Varicella (Chicken Pox)	8	1	5	3	2	1	20


Counts of Disease With Sufficient Burden: Philadelphia, 2020

*Public health deems that this reportable disease still poses a serious risk to the population by reason of their contagiousness, severity, or frequency.

CENTRAL DERVOUS SYSTEM INFECTIONS AND SEPSIS

GROUP A STREPTOCOCCUS HAEMOPHILUS INFLUENZAE LISTERIOSIS MENINGITIS, ASEPTIC STREPTOCOCCUS PNEUMONIAE


GROUP A STREPTOCOCCUS



Number of Invasive *Group A Streptococcus* by Age and Gender: Philadelphia, 2020

	0-30 Years		31-45 Years		-	-65 ears		6+ ars	Total		
	n %		n	%	n	%	n	%	n	%	
Male	19	10.6	21	11.7		8.9	18	10.1		41.3	
Female	18	10.1	42	23.5	33	18.4	12	6.7	105	58.7	
Total	37	20.7	63	35.2	49	27.4	30	16.8	179	100	


HAEMOPHILUS INFLUENZAE



Number of Invasive *Haemophilus influenza* by Age: Philadelphia, 2020

	0- Ye	- 34 ears	35 - Ye	-60 ears	6 Ye	O+ ears	Total		
	n	%	n	%	n	%	n	%	
Total	n % 7 29.2		10 41.7		7 29.2		24 100		

LISTERIOSIS (Listeria monocytogenes)




* https://www.cdc.gov/nchs/healthy_people/hp2020.htm

**CDC FoodNet is the Foodborne Diseases Active Surveillance Network, utilizing sentinel data to monitor trends in foodborne diseases

MENINGITIS, ASEPTIC


(Pleocytosis in cerebroprinal fluid and no bacterial, fungal or parasitic organisms on culture)



Number of Aseptic Meningitis Reports by Age: Philadelphia, 2020



STREPTOCOCCUS PNEUMONIAE



OF NOTE

Among 6 invasive pneumococcal cases 14 years and younger, 5 cases (83%) were up to date on the pneumococcal conjugate vaccine. One fatality occurred in a 3-week-old infant who had not yet received pneumococcal conjugate vaccine due to age. Four cases of those 14 years of age and younger had serotyping completed. One pediatric case who received Pneumococcal Conjugate Vaccine 13 prior to illness was infected with a serotype (19A) included in the vaccine. The other three cases did not have prior vaccination against serotypes identified. Isolates from 121 cases in 2019 had antibiotic resistance testing, of which 20 (17%) were fully or intermediately resistant to at least one antimicrobial agent currently approved for treatment pneumococcal infection.

Number of Invasive *Streptococcus pneumoniae* by Age and Gender: Philadelphia, 2020


		- 29 ears	30-49 Years			- 59 ears		-69 ears		70+ Years		tal
	n	%	n	%	n	%	n	%	n	%	n	%
Male		4.9	12	9.8	15	22.2	19	15.4	13	10.6	65	52.8
Female	6	4.9	8	6.5	16	13.0	18	14.6	10	8.1	58	47.2
Total	12	9.8	20		31	25.2	37	30.1	23	18.7	123	100

Intentionally Left Blank

GASTRO-INFECTIONS

OVERVIEW CAMPYLOBACTERIOSIS CRYPTOSPORIDIOSIS GIARDIASIS SALMONELLOSIS SHIGELLOSIS

OVERVIEW




OVERVIEW (Cont.)

Pathogen	Antibiotics Tested	Total Tested	Resi	stant	Interm	ediate
	resteu	Testeu	n	%	n	%
Commulations	Ciprofloxacin	15	4	27	0	ο
Campylobacter	Erythromycin	15	ο	ο	ο	0
	Ampicillin	101	10	10	1	1
	Ceftriaxone	72	0	0	0	0
Salmonella	Ciprofloxacin	57	2	4	3	5
	Levofloxacin	36	0	0	3	8
	Trimethoprim- Sulfamethoxazole	100	4	4	0	0
	Ampicillin	44	37	84	0	0
	Ceftriaxone	27	1	4	0	0
	Ciprofloxacin	42	9	21	3	7
Shigella	Gentamicin	16	16	100	0	0
	Levofloxacin	27	2	7	8	30
	Trimethoprim- Sulfamethoxazole	42	37	88	0	ο

Antibiotic Resistance of Selected Enteric Pathogens: Philadelphia, 2020

Results of antimicrobial susceptibility testing show if bacteria are susceptible (can be treated with the drug), intermediate (may be treatable with the drug, but may require adjusted dosage), or resistant (cannot be treated with drug). https://www.cdc.gov/narms/resources/glossary.html#:~:text=Results%20of%20antimicrobial%20susceptibility%20testing,cannot%20be%20treated%20with%20drug).


CAMPYLOBACTERIOSIS (Campylobacter spp.)



Number of Campylobacteriosis Reports by Age and Gender: Philadelphia, 2020

	0-4 Years		5-24 Years		25-49 _{Years}			-65 ears		6+ ears	Total [.]	
	n %		n	%	n	%	n	%	n	%	n %	
Male	22	11.2	8	4.1	27	13.7	29	14.7	16	8.1	102	51.8
Female	16	8.1	15	7.6	28	14.2	21	10.7	15	7.6	95	48.2
Total	38	19.3	23	11.7	55	27.9	50	25.4	31	15.7	197	100

CRYPTOSPORIDIOSIS (Cryptosporidium spp.)




*Since 2017, CDC FoodNet no longer includes surveillance for Cryptosporidiosis.

	0- Ye	- 24 ears	25	-39 ears	4 (Ye	O+ ears	Total Years		
	n %		n	%	n %		n	%	
Total	6 25.0		7 29.2		11 45.8		24	100	
	0 23.0								

Number of Cryptosporidiosis Reports by Age: Philadelphia, 2020


GIARDIASIS (Giardia lamblia)



Number of Giardiasis Reports by Age: Philadelphia, 2020

		-14 ears	15-29 Years		30-39 Years		40-49 Years		50+ Years		Total	
	n	%	n	%	n	%	n	%	n	%	n	%
Total	7	14.9	16	34.0	12	25.5	6	12.8	6	12.8	47	100

SALMONELLOSIS (Salmonella spp.)




OF NOTE

In late 2020, PDPH and the Pennsylvania Department of Health (PADOH) investigated a multistate Salmonella Typhimurium outbreak associated with small pet turtles. During 2020, 9 laboratory-confirmed cases from PA were identified, of whom, 4 were Philadelphia residents. All 4 cases from Philadelphia reported owning small red-eared slider turtles. Three of the Philadelphia cases were children under the age of 5 and one was an adult resident. Among the cases in PA where purchase location of the turtle was known, most were reported to be roadside vendors in Philadelphia. In early 2021, both PDPH and PADOH issued health advisories to notify healthcare providers of the outbreak.


Number of Salmonellosis Reports by Age and Gender: Philadelphia, 2020

	0-4 Years		5-17 S Years		18-34 Years		35-59 Years		60+ Years		Total	
	n	%	n	%	n	%	n	%	n	%	n	%
Male	22	12.6	12	6.9	10	5.7	21	12.1	15	8.6	80	46.0
Female	27	15.5	12	6.9	19	10.9	18	10.3	18	10.3	94	54.0
Total	49	28.2	24	13.8	29	16.7	39	22.4	33	19.0	174	100

SALMONELLOSIS (Cont.)



SHIGELLOSIS (Shigella spp.)



Number of Shigellosis Reports by Age: Philadelphia, 2020

	0-5 Years		6- Ye	6-20 Years		-34 ears	3 Ye	35+ Years		tal
	n	%	n	%	n	%	n	%	n	%
Total	7	9.0	10	12.8	33	42.3	28	35.9	78	100

HEALTHCARE ASSOCIATED

INFECTIONS

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE

OVERVIEW


OF NOTE

The Healthcare-Associated Infections/Antimicrobial Resistance (HAI/ AR Program), established in late 2016, is dedicated to the prevention and control of Healthcare-Associated Infections (HAIs) and Antimicrobial Resistance (AR). This Program serves as a resource to the Philadelphia healthcare community and public with the goal of improving healthcare safety and quality in the city of Philadelphia.

The HAI/AR Program, works on topics including, but not limited to: infections transmitted in healthcare settings and associated with healthcare; drug-resistant organism surveillance, prevention, and containment; infection prevention and control assessments and guidance in healthcare settings; healthcare worker (HCW) safety, including HCW exposures and immunization policies, and infection control education; antimicrobial stewardship in healthcare settings; antibiotic education for the general public.

HEALTHCARE-ASSOCIATED INFECTIONS 2020

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)



CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)

Genus Species	n (%)	Total CP-CRE	Mechanism of Resistance (n)				
		CP-CRE	KPC*	NDM*	IMP*	VIM*	OXA-48*
Klebsiella pneumoniae	115 (49)	69	67	2			
Enterbacter cloacae	39 (17)	16	15		1		
Escherichia coli	33 (14)	21	8	11			2
Enterobacter aerogenes	11 (5)	1	1				
Serratia marcesens	3 (1)	1	1				
Citrobacter freundii	5 (2)	4	4				
Klebsiella oxytoca	7 (3)	4	4	1			
Citrobacter koseri	1 (1)		0				
Other Citrobacter spp	3 (1)	1	1	1			
Citrobacter amalonaticus	4 (2)	2	2				
Other Enterobacteriaceae	8 (3)						
Raoultella Spp.	1 (1)	1	1				
Total	234	124	105	18	1	0	2

*KPC = Klebsiella pneumoniae carbapenemase

*NDM = New Delhi metallo-ß-lactamase

*IMP = Imipenemase metallo-ß-lactamase


*VIM = Verona integron-encoded metallo-ß-lactamase

*OXA-48 Like = Oxacillinase-48 like

RESPIRATORY INFECTIONS

INFLUENZA LEGIONELLOSIS TUBERCULOSIS


INFLUENZA



Number of Hospitalized Influenza Reports by Age and Region: Philadelphia, 2020-2021

	NE		NW		Ν		CC		S		W/SW		Total	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Age														
0-4 Yrs	14	1.4	<6		26	2.6	<6		<10		28	2.8	78	7.7
5-17	11		<6		22	2.2	<6		<6		<6		44	4.3
18-44 Yrs	34	3.3	9	0.9	98	9.6	8	0.8	21	2.1	37	3.6	207	20.4
45-64	60	5.9	16	1.6	134	13.2	12	1.2	33	3.2	73	7.2	328	32.3
65+ Yrs	95	9.3	19	1.9	107	10.5	21	2.1	57	5.6	61	6.0	360	35.4
Total	214	21.0	47	4.6	387	38.1	43	4.2	122	12.0	204	20.1	1,017	100.0
Rate**	60		46		72		63				75		95.5	
						h Phila per 100		a's rate	e is cor	nbinec	l with C	Center	City's rai	e


LEGIONELLOSIS (Legionella pneumophila)



Number of Legionellosis Reports by Age: Philadelphia, 2020

	0- Ye	• 50 ears	51. Ye	-64 ears	6 Ye	5+ ears	Total		
	n %		n	%	n	%	n	%	
Total	10	25.6	14	35.9	15	38.5	39	100	






Number of Tuberculosis Reports by Age: Philadelphia, 2020


	0- Ye	- 30 ears		-44 ears		-65 ears	6 Y	6+ ears	Тс	otal
	n	%	n	%	n	%	n	%	n	%
Total		13.1	12	19.7	26	42.6	15	24.6	61	100

SEXUALLY TRANSMITTED DISEASES


OVERVIEW CHLAMYDIA GONORRHEA SYPHILIS-PRIMARY & SECONDARY SYPHILIS-LATENT

OVERVIEW






OVERVIEW (Cont.)




Percent of Philadelphia Public High School Students Testing Positive for Chlamydia and/or Gonorrhea: Philadelphia, by School Year 2009-2020

	09-10	10-11	11-12	12-13	13-14	14-15	15-16	16-17	17-18	18-19	19-20
	%	%	%	%	%	%	%	%	%	%	%
Male	3.9	4.4	4.5	3.4	2.8	3.1	3.9	3.4	2.4	3.0	3.1
Female	9.7	10	10	7.8	7.5	7.1	6.6	6.3	6.1	6.9	6.1
Total	6.6	6.9	6.9	5.4	4.8	4.9	4.6	4.7	4.0	4.7	4.5

CHLAMYDIA (Chlamydia trachomatis)



CHLAMYDIA (Cont.)




Number of Chlamydia Reports by Age, Gender, and Region: Philadelphia, 2020


	Ν	E	N	W	N		С	С		5	W/9	SW	Tota	aľ
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Male							1		1					
0-14 Yrs	<6		<6		18	0	<6		<6		10	0	31	1
15-19 Yrs	214	3	36	1	741	12	18	0	52	1	341	6	1,402	23
20-24 Yrs	422	7	73	1	809	13	52	1	102	2	404	7	1,862	30
25-34 Yrs	359	6	66	1	873	14	149	2	199	3	461	7	2,107	34
35+ Yrs	123	2	27	0	333	5	78	1	89	1	139	2	789	13
Female														
0-14 Yrs	14	0	6	0	100	1	<6		<10		31	0	162	2
15-19 Yrs	328	4	102	1	1,675	18	53	1	165	2	673	7	2,996	33
20-24 Yrs	410	5	133	1	1,554	17	81	1	184	2	730	8	3,092	34
25-34 Yrs	351	4	81	1	1,143	13	101	1	133	1	499	6	2,308	25
35+ Yrs	75	1	14	0	267	3	18	0	35	0	97	1	506	6
Grand Total	2,299	15	538	3	7,519	49	553	3	969	6.4	3,385	22	15,263	

'unknown=571

GONORRHEA (Neisseria gonorrhoeae)




GONORRHEA (Cont.)




Number of Gonorrhea Reports by Age, Gender, and Region: Philadelphia, 2020

	Ν	E	N	w	N	I	С	с	S	5	W/9	SW	То	tal'
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Male														
0-14 Yrs	<6		<6		<6		<6		<6		8	0	15	0
15-19 Yrs	79	2	11	0	327	7	13	0	30	1	161	4	621	14
20-24 Yrs	147	3	30	1	481	11	28	1	56	1	273	6	1,015	23
25-34 Yrs	184	4	61	1	739	16	115	3	209	5	433	10	1,741	39
35+ Yrs	111	2	39	1	447	10	89	2	166	4	233	5	1,085	24
Female														
0-14 Yrs	<6		<6		38	2	<6		<6		17	1	67	3
15-19 Yrs	60	2	19	1	437	17	14	1	34	1	170	7	734	29
20-24 Yrs	64	3	24	1	383	15	12	0	32	1	191	8	706	28
25-34 Yrs	83	3	24	1	383	17	24	1	46	2	178	7	738	29
35+ Yrs	34	1	7	0	137	5	13	1	8	0	62	2	261	10
Grand Total	767	11	219	3	3,378	48	311	4	585	8	1,726	25	6,986	100
L. L	1												¹ unkno	wn=316

SYPHILIS-PRIMARY & SECONDARY (Treponema pallidum)




SYPHILIS-PRIMARY & SECONDARY (Cont.)



Number of Primary & Secondary Syphilis Reports by Age and Region: Philadelphia, 2020

	N	E	N	W	1	1	С	С	5	5	W/	sw	То	tal
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Age														
0-24 Yrs	15	3	<6		49	10	<6		7	1	26	5	106	22
25-34 Yrs	8	2	8	2	88	18	22	4	24	5	57	12	207	42
35+ Yrs	25	5	8	2	61	12	27	6	24	5	33	7	178	36
Total	48	10	20	4	198	40	54	11	55	11	116	24	511	100
											7		*Miss	ing 20


SYPHILIS-EARLY LATENT (*Treponema pallidum*)




Number of Early Latent Syphilis Reports by Age and Region: Philadelphia, 2020

	Ν	E	NW		N		С	С	9	5	w/	SW	Tot	tal [.]
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Age														
0-24 Yrs	14	2	<6		58	10	<6		<6		22	4	103	18
25-34 Yrs	20	3	15	3	122	21	<25		30	5	63	-11	272	46
35+ Yrs	20	3	10	2	71	12	19	3	48	8	44	8	212	36
Total	54	9	27	5	251	43	43	7	83	14	129	22	587	100
													[•] unkn	own=!

SYPHILIS-EARLY LATENT (Cont.)




Primary & Secondary and Early Latent Syphilis Cases by Year and Risk Group: Philadelphia, 2009-2020



VACCINE-PREVENTABLE DISEASES

CHICKEN POX MENINGOCOCCAL DISEASE PERTUSSIS

CHICKEN POX (Varicella zoster virus)




CHICKEN POX (Cont.)

Number of Chicken Pox Reports by Age: Philadelphia, 2020

	0 Ye	-3 ears	4 - Ye	- 19 ears	20+ Years		То	Total	
	n	%	n	%	n	%	n	%	
Total	8	40.0	6	20.0	6	20.0	20	100	

MENINGOCOCCAL DISEASE

(Neisseria meningitidis)




In 2020, 8,941 individuals aged 16-23 years from Philadelphia received ≥ 1 dose of meningococcal B vaccine, which provides short-term protection against most strains of serogroup B meningococcal disease. It should be noted that meningococcal B vaccine is administered following shared clinical decision making between the provider and the patient (Category B Recommendation).

PDPH identified a total of 15 cases of meningococcal disease (14 confirmed and 1 suspect) in 2020. This was a marked increase of 400% from a mean of 3 cases reported annually from 2011-2019 (range 0-6 cases). No outbreaks were identified in 2020 and therefore, the increase was due to ongoing community transmission. Of note, cases were primarily adults (14, 93%), and the median age was 53 years (range: 3-79 years). Seven cases (47%) occurred among persons experiencing homelessness. Serogrouping was completed for all 14 confirmed cases, with Neisseria meningitidis group C being the primary serogroup identified (12, 86%).


			-		•p	.,	10 20					
	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Total N (%)
Serogroup												
В				0		0			0			10 (23%)
с	1	0	1	0	0	0	0	о	0	о	12	14 (33%)
w	0	0	0	0	0	0	0	0	0	0	0	0 (0%)
х	0	1	0	0	0	0	0	0	0	0	0	1 (2%)
	2	2	2	2	0	0	0	0	0			10 (23%)
z	0	0	0	0	0	0	0	0	0	0	0	0 (0%)
Nontypeable	1	0	1	1	1	0	1	0	1	2	0	8 (19%)
Total	5	4	6	3	2	0	2	0	1	6	14	43 (100%)

Reports of Meningococal Disease by Serogroup Per Year: Philadelphia, 2010-2020

MUMPS



PERTUSSIS (Bordetella pertussis)




Number of Pertussis Reports by Age: Philadelphia, 2020

	0 Ye	0-4 Years		-17 ears	18 Ye	3+ ears	Total		
	n	%	n	%	n	%	n	%	
Total	11	34.4	11	34.4	10	31.3	32	100	

VECTOR-BORRNE DISEASES

TICKBORNE INFECTIONS ARBOVIRAL INFECTIONS ZIKA VIRUS LYME DISEASE MALARIA WEST NILE VIRUS




Reported Cases of Other Non-Lyme Tickborne Infections: Philadelphia, 2016-2020

	2016	2017	2018	2019	2020	Total
Anaplasmosis	3	4	4	4	0	15
Babesiosis*	2	5	4	4	3	18
Ehrlichiosis	2	2	0	1	0	5
Rocky Mountain Spotted Fever	5	7	3	8	1	24
Total	12	18	11	17	4	62

*All infection include locally-acquired and travel-associated infections. Babesiosis also includes transfusion-associated cases.

ARBOVIRAL INFECTIONS




Demographics of Travel Associated Arboviral Infections: Philadelphia, 2014-2020

	Chik	ungunya	Der	ngue
	n= 44	%	n= 36	%
Female	34	77	10	28
Foreign Born	31	70	8	23
Median Age (Range) Years	42.5	(5-78)	35.5	(5-64)

Outcomes of Travel-associated Arboviral Infections: Philadelphia, 2014-2020


	Chiku	ingunya	Den	gue
	n= 44	%	n= 36	%
Hospitalized	9	20	13	37
Death	0	0	о	0



Number of Lyme Disease Reports by Age and Gender: Philadelphia, 2020

		- 15 ars		- 34 ears		- 60 ars]+ ears	То	tal	
	n	%	n	%	n	%	n	%	n	%	
Male	16	11.2	19	13.3	26	18.2	18	12.6	79	55.2	
Female	6	4.2	18	12.6	17	11.9	23	16.1	64	44.8	
Total	22	15.4	37	25.6	43	30.1	41	28.7	143	100	





*Includes one cryptic case with unknown source of infection and one congenital case

VECTOR-BORNE DISEASES

WEST NILE VIRUS


OF NOTE

During the 2020 season, 4 Philadelphia residents developed West Nile Virus (WNV) infections (4 neuro-invasive WNV and 0 WNV fever). All cases occurred in adults >50 years of age and required hospitalization. Cumulative WNV positivity in mosquitoes collected during the 2020 season was higher than 2019 (16% vs 12%), and higher than the historic median rates (5%).

HERALDANE INFECTIONS

HEPATITIS A HEPATITIS B & C-ACUTE HEPATITIS B-CHRONIC HEPATITIS B & C-PERINATAL HEPATITIS C-CHRONIC

HEPATITIS A (Hepatitis A virus)



OF NOTE

In 2020, PDPH identified 25 confirmed cases of hepatitis A. Under one-third of the cases occurred among persons who use drugs and persons experiencing homelessness (8, 32%). Median age of the hepatitis A cases was 38 (range: 20 - 85 years). Most hepatitis A cases were hospitalized (21, 84%) and 2 (8%) infections were fatal. The decline in hepatitis A cases during 2020 was likely due to a combination of COVID-19 Safer At Home mitigation strategies and possible under recognition of infections.

HEPATITIS-ACUTE

(Hepatitis B & C virus) Rates of Reported Acute Hepatitis B: Philadelphia and United States, 2011-2020


- --- Philadelphia
----- United States
*Totals for 2020 were likely to have been impacted by the COVID-19 pandemic.

'13

'14

'12

'11



'15

YEAR OF REPORT

'17


'16

'18

'19

'20 *

*Totals for 2020 were likely to have been impacted by the COVID-19 pandemic.



Number of Newly-reported Chronic Hepatitis B Reports by Age and Gender: Philadelphia, 2020

	-	0-30 Years																- 45 ars	-	- 65 ars		6+ ars	Tot	tal*
	n	%	n	%	n	%	n	%	n	%														
Male	33	7.5	104	23.7	102	23.2	43	9.8	282	64.2														
Female	37	8.4	56	12.8	40	9.1	24	5.5	157	35.8														
Total	70	15.6	160	36.5	142	32.4	67	15.3	439	100														
								*19 ł	had mis	sing age														

HEPATITIS-PERINATAL (Hepatitis B & C virus)

Comparison of Perinatal Hepatitis B: Philadelphia 2011-2019

	2011	2012	2013	2014	2015	2016	2017	2018	2019
Total Birthing Person-Infant Pairs Followed	131	171	153	164	155	174	131	139	128
Total Children Receiving HBIG** Within One Calendar Day of Birth	129 (98%)	154 (90%)	140 (92%)	23 (14%)	81 (52%)	157 (90%)	118 (90%)	135 (97%)	112 (88%)
Total Children Receiving Birth HepB Vaccine Within One Calendar Day of Birth	129 (98%)	167 (98%)	150 (98%)	22 (23%)	128 (83%)	163 (94%)	121 (92%)	139 (100%)	122 (95%)
Total Children Receiving 3 HBV Vaccines in 1 Year	114 (87%)	167 (98%)	134 (88%)	139 (85%)	120 (77%)	154 (89%)	121 (92%)	124 (92%)	112 (88%)
Children HBsAg+*** at Screening (9–12 months old)	0	1 (<1%)	0	0	1 (<1%)	0	0	0	0

**HBIG: Hepatitis B Immunoglobulin

***HBsAg+: Hepatitis B surface antigen positive

OF NOTE

The Perinatal Hepatitis B Prevention Program offers education and case management services to any person who is pregnant/gives birth and has hepatitis B. This follow up extends to the infant until they are fully screened for hepatitis B infection and immunity.


*In 2014, the quality of HBIG and birth dose of hepatitis B vaccine data was insufficient and not accepted for many infants. However, PDPH does not expect there was a meaningful gap in services offered to infants that year.

Hepatitis C-positive Babies After Perinatal Exposure: Philadelphia, 2019

Year of Birth	Number Known Exposed	Infants with Completed Screening*	Infants Positive after Perinatal Exposure
2018	107	60	5
2019	91	50	1

OF NOTE
In 2016, PDPH formed the nation's first Perinatal Hepatitis C Program . The program aims to work with healthcare providers and birthing per- sons to: (1) identify hepatitis C-positive pregnant people, (2) encourage them to receive hepatitis C care, (3) work to ensure infants are tested appropriately for hepatitis C, (4) ensure hepatitis C-positive infants are linked to a specialist, and (5) characterize perinatal hepatitis C in Philadelphia.

HEPATITIS C-CHRONIC (Hepatitis C virus)



Number of Newly-reported Chronic Hepatitis C Reports by Age and Gender: Philadelphia, 2020

	0-30 Years		31-45 Years		46-65 Years		66+ Years		Total*	
	n	%	n	%	n	%	n	%	n	%
Male	87	6.8	293	22.9	306	24.0	182	14.2	868	67.8
Female	71	5.6	135	10.6	131	10.2	75	5.9	412	32.1
Total	158	12.3	428	33.4	437	34.1	257	20.1	1,280	100

*8 had missing age

REPORTING DISEASES & CONDITIONS

NOTIFIABLE DISEASE LIST REPORT FORM



Call (215) 686-4514 for immediate reporting and consultation after hours, on weekends, and holidays Please note that you will need to press 1 for Unified Dispatch and ask to be connected with the Division of Disease Control on-call staff

REPORTABLE DISEASES AND CONDITIONS

Acute flaccid myelitis Amebiasis

Animal bites (wild/stray/domestic) Anthrax*

Babesiosis Arboviruses

Botulism* Brucellosis*

Campylobacteriosis

Candida auris

Chancroid Enterobacteriaceae (CRE) Carbapenem-resistant

Chikungunya

lymphogranuloma venereum Chlamydia trachomatis including

Cholera*

Dengue Encephalitis* Ehrlichiosis/Anaplasmosis Cryptosporidiosis Creutzfeldt-Jakob Disease Diphtheria* Cyclosporiasis

Food poisoning* Giardiasis Escherichia coli O157:H7 and Shiga toxin-producing bacteria

> Haemophilus influenzae, invasive Guillain-Barré Syndrome Gonococcal infections

Staphylococcus aureus, vancomycin

Smallpox* Shigellosis

Hantavirus Pulmonary Syndrome* disease'

Hepatitis A Hemorrhagic fever, all

in a Hepatitis C infected woman Hepatitis C, also including: pregnancy Hepatitis B, also including: pregnancy Hepatitis, other viral in a Hepatitis B infected woman

Human immunodeficiency virus (HIV/ Histoplasmosis

- AIDS) ‡, also including: acute HIV infection*+
- birth of an infant to an HIV infected woman*,
- new HIV positive result in a pregnant woman^{*}, and
- pregnancy in an HIV infected woman*^

Influenza (including novel influenza A*, pediatric deaths*, and institutional

outbreaks*) Leprosy (Hansen's disease) Legionellosis Lead poisoning +

> typhus fever) Mountain spotted fever, rickettsial pox, Rickettsial diseases (including Rocky Psittacosis (ornithosis) Poliomyelitis* Plague* Pertussis (whooping cough) Pandrug-resistant organism* pregnant persons)* Novel coronaviruses (SARS, MERS-CoV Neonatal Abstinence Syndrome (NAS) Mumps SIW) Multisystem Inflammatory Syndrome Meningococcal infections* Meningitis (viral, fungal, bacterial) Lyme disease Leptospirosis Rabies* COVID-19 including infections in Mpox* Melioidosis* Measles (rubeola)* Malaria Listeriosis

group B (infants 0-89 days of age) Toxic Shock Syndrome Streptococcus pneumoniae, invasive A Streptococcal disease, invasive Streptococcal disease, invasive group paratyphi)* Tuberculosis § Syphilis disease Insensitive Tularemia* Trichinosis Tetanus

Typhoid (Salmonella typhi and

Varicella, including zoster Vibriosis

West Nile Virus

Yellow Fever*

Zika, including prenatal and postnatal Yersiniosis

congenital Zika infection birth defects associated with

Mandatory reporting of all immunizations administered to all individuals of all ages in the City of Philadelphia to PhilaVax, the City-wide immunization information system, at vax.phila.gov

Salmonellosis

Rubella*

Rubella (German Measles) & Congenital

Report suspected and confirmed cases within 24 hours. All unusual disease clusters, disease outbreaks, and unusual disease occurrences should be reported immedi

Report to TB Control Program at (215) 685-6873 Report to Lead Poisoning Prevention at (215) 685-2788

AReport to AIDS Activities Coordinating Office at #(215) 685-4789, +(215) 685-4781, or A(215) 685-4766, based on result/event type

Organism is pan-drug resistant if it exhibits non-susceptibility to all antibacterial or antifungal agents tested

Fax: (215) 238-6947 Phone: (215) 685-6748

Patient Name | Condition | Age/DOB, Sex, Address & Phone | Clinician Name, Address & Phone | Laboratory Results To report a case to DDC, call, fax, or submit through PA-NEDSS the following information:

Effective: 08/2023

Notifiable I	Disease	Case Re	eport (Con		Philadelphia Department of Public Health Division of Disease Control Acute Communicable Disease Program 1101 Market St, 12th Floor, Philadelphia, PA 19107						
					t Informa	tion					
Report Date (<i>Mo.,</i>	Day, Yr.)		Name <i>(Last, I</i>	First, M.I.)			Parent or caretaker (if	applicable)			
	/										
/	/						Telephone				
							(Cell)				
DOB (Mo., Day, Yr	:)	Age	Sex		Occupatio	n					
//	-		Male	Female			(Work)				
Name of Employer	or School			Madia		,	Number, Street, City, Zip Co	de)			
Disease or Condition	on			Medica	al Informa						
Disease of Condition	UII				Date of Or	nset (Mo., Day, Yr	, s	Fatal (check one)			
						1 1	Clinical	☐ No ☐ Yes			
						//		Date of Death			
Chief Symptoms /	Complaints					Suspected sour	ce(s) of Infection (if known)				
	nausea	diarrhea		joint pain		School/dayca		park/outdoors			
	vomiting	fever	body ache			vork	restaurant	recreational water			
						 ☐ travel (where	e/dts:	_)			
If Case Hospitalize	d (Name of	Hospital/Med	ical Provider)				Admission Date	Discharge Date			
							//	//			
		La	boratory Info	rmation If Pe	rtinent <i>(a</i>	ttach copies if	applicable)	<u>.</u>			
Name of Lab	Nam	e of Test		Site Source		Result	Collection Date	Result Date			
			Blood	Stool							
			CSF	Other							
			Blood	Stool							
			CSF	Other							
			Blood	Stool							
Antibioti	. Consitin	itian /if ann		Other			Notoo				
		ities (if app	-				Notes				
Antibiotic Ampicillin		Intermediat	e Susceptible								
Ceftriaxone											
Ciprofloxacin											
Levofloxacin		П									
Penicillin											
Trimethoprim/											
Sulfamethoxazole											
(Bactrim)				Report	er Inform	ation					
Facility Name			Reporter Nam			Reporter Phone	# Reporter				
, .			,				ICP ED	School Nurse			
			DO NOT WE	RITE IN AREA P	BELOW - E	OR DEPARTMEN					
Name (Person Red	ceivina Ren	ort)		Method of rep							
		7			Fax	Mail	Other				
Any unusu	al illness.	, disease cl	usters or pos				immediately by telepho	ne. Please fax all			
Revised 06/14/			ed reports to	215-238-6947	or call 2	15-685-6748 to	report by phone. ease use specific form.				